Publications
To view a full list of publications, please see Dr. Byrne's PubMed Bibliography
Selected publications
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment
Maltez VI, Arora C, Gribbin KP, Caruso B, Haerr ME, Sor R, Lian Q, Blies KE, Sivagnanam S, Sears RC, Coussens LM, Vonderheide RH, Germain RN†, Byrne KT†. Immunity. In Press. DOI: 10.1016.j.immuni.2026.03.011
CD4 T cells mediate rejection of MHC I-deficient tumor cells
Kim SI*, Haerr ME*, Al-Ghezi M, Arora C, Gribbin KP, Chen C, Xia Z, Vonderheide RH, Byrne KT. Cancer Immunology Research. 14 (1): 107-121. doi: 10.1158/2326-6066.CIR-24-1342..
CD4 T cells mediate rejection of MHC I-deficient2026.03.011 tumor cells
Kim SI*, Haerr ME*, Al-Ghezi M, Arora C, Gribbin KP, Chen C, Xia Z, Vonderheide RH, Byrne KT. Cancer Immunology Research. 14 (1): 107-121. doi: 10.1158/2326-6066.CIR-24-1342.
Machine learning links T cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer
Blise KE, Sivaganam S, Betts CB, Betre K, Kirchberger N, Tate B, Furth EE, Dias Costa A, Nowa JA, Wolpin BM, Vonderheide RH, Goecks J†, Coussens LM†, Byrne KT†. Cancer Immunology Research. 12(5):544-558, 2024. doi: 10.1158/2326-6066.CIR-23-0873.
T cell inflammation in the tumor microenvironment after neoadjuvant agonist CD40 antibody in patients with resectable pancreatic cancer
Byrne KT*, Betts CB*, Mick R*, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O’Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Clinical Cancer Research, 27(16):4574-4586, 2021.
CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity
Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. JCI Insight, 5(10):e137263, 2020.
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Morrison AH, Diamond MS, Hay CA, Byrne KT†, Vonderheide RH†. Proceedings of the National Academy of Sciences, 117(14):8022-8031, 2020.
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Hay CA, Sor R, Flower AJ, Clendenin C, Byrne KT. Journal of Visualized Experiments, (153), e60479, 2019.
Tumor cell-intrinsic factor underlie heterogeneity of immune cell infiltration and response to immunotherapy
Li J*, Byrne KT*†, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Coussens LM, Wherry EJ, Vonderheide RH†, Stanger BZ†. Immunity, 49(1):178-193, 2018.
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne KT and Vonderheide RH. Cell Reports, 15(12):2719-32, 2016.
* denotes shared first authorship
† denotes shared corresponding authorship